Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 11/20 | 0.54 |
| ▸ | PPARA | Q07869 | 10/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10480743 | 0.89 | HRH3 (0.58) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL27642186 | 0.89 | KDM4E (0.55) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL10058004 | 0.83 | HRH3 (0.62) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL6830199 | 0.83 | HRH3 (0.58) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL4389491 | 0.82 | HRH3 (0.61) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL979145 | 0.82 | KDM4E (0.65) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL10480770 | 0.82 | HRH3 (0.61) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL5537439 | 0.82 | HRH3 (0.61) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL1436970 | 0.82 | HRH3 (0.61) | HRH3KDM4EPPARGPPARAHPGD | |
| SCHEMBL5738511 | 0.81 | KDM4E (0.60) | HRH3KDM4EPPARGPPARAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772264-B2 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1888571-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | DPP4, DPP3, DPP9 | HRH3 3570/4885KDM4E 1304/4885PPARG 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.